期刊文献+

人乳头状瘤病毒核酸分型检测试剂的研究进展 被引量:13

Molecular detection and genotyping of human papillomavirus
原文传递
导出
摘要 高危型人乳头状瘤病毒(HPV)的持续性感染是引起宫颈癌的主要原因。分子生物学检测HPV核酸DNA或RNA,可用于HPV的流行病学调查、疫苗的效力评价和宫颈癌的筛查。许多商业化的HPV核酸(分型)检测试剂盒基于不同的方法学和检测系统,从原理上主要包括两大类,即信号放大法和靶向扩增法,大多数以PCR扩增为主,不同检测试剂的性能存在一定的差异。目前,基于二代测序和定量HPV核酸检测试剂也在不断研究中,只有少量试剂在临床上进行了验证,大量的试剂亟需进行临床适用性验证,从而发挥更大的临床价值。 The development of cervical cancer is associated with persistent infection of high-risk human papillomavirus. The detection and genotyping of HPV could be used to evaluate the epidemiology of HPV infections, monitor HPV vaccine efficacy, and screen cervical cancer. There are a lot of commercially available molecular tests for HPV, based on different methodologies and detection systems. In principle, it mainly includes two categories, namely signal amplification and target amplification. Most of them are based on PCR amplification, such as fluorescent PCR, PCR-reverse hybridization, etc. The performances of detection reagents are different. In addition, HPV genotyping assays based on next-generation sequencing and quantitative HPV detection kits are developed. However, only a small number of commercial assays have been clinically verified. A large number of assays which may bring greater values in the screening of cervical cancer are needed to be clinically validated.
作者 田亚宾 张春涛 Tian Yabin;Zhang Chuntao(Division Ⅱ of In Vitro Diagnostics for Infectious Diseases,National Institutes for Food and Drug Control,Beijing 100050,China)
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2018年第10期729-735,共7页 Chinese Journal of Oncology
基金 中国食品药品检定研究院中青年发展研究基金(2017C2)
关键词 人乳头状瘤病毒 分型检测 细胞学 靶向扩增法 Human papillomavirus Genotyping Cytology Target amplification
  • 引文网络
  • 相关文献

参考文献3

二级参考文献45

  • 1陈汶,刘彬,戎寿德,乔友林.人乳头状瘤病毒DNA检测进展[J].中华检验医学杂志,2005,28(5):552-554. 被引量:17
  • 2李旻,曹箭,王乃鹏,李龙玉,李凌,乔友林,潘秦镜.p16^(INK4a)免疫细胞化学检测在筛查宫颈癌中的作用[J].中华肿瘤杂志,2006,28(9):674-677. 被引量:9
  • 3Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papiUomavirus (HPV) infections. J Clin Virol, 2005, 32 Suppl 1 : S43 -51.
  • 4Wright TC Jr, Massad LS, Dunton C J, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol, 2007, 197 : 346- 355.
  • 5Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology, 2008, 19:342-354.
  • 6ACOG Praciice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol, 2009, 114 : 1409-1420.
  • 7Stoler MH, Wright TC, Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol, 2011, 135: 468-475.
  • 8Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: a meta- analysis of the HPV test positivity rate. J Cell Mol Med, 2009, 13:648-659.
  • 9Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV-DNA detection : triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol, 2005, 99 :S7-11.
  • 10de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11 : 1048- 1056.

共引文献109

同被引文献118

引证文献13

二级引证文献45

;
使用帮助 返回顶部